WCN26-6468 COMPARATIVE EFFECTIVENESS OF GLP-1RAs VS. MRAs AS FOURTH-LINE THERAPY FOR RESISTANT HYPERTENSION

Read full text Summarise with VIRAT
Authors: Bernhard Schmidt, Zhejia Tian, Kai M. Schmidt-Ott, Anette Melk
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Resistant hypertension accelerates hypertension-mediated organ damage and is associated with increased cardiovascular risk and mortality. Previous studies have shown that resistant hypertension is more prevalent among overweight and obese individuals. Notably, large randomized controlled trials have reported blood pressure-lowering effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), suggesting that GLP-1RAs may represents a promising therapeutic option in this population. This study aims to compare the effectiveness of GLP-1RAs (semaglutide and tirzepatide) and mineralocorticoid receptor antagonists (MRAs, spironolactone and eplerenone) in reducing major adverse cardiovascular effect (MACE) among individuals with resistant hypertension.

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Hormonal Regulation and Hypertension Diabetes Treatment and Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105760–105760
Publication date
25 March 2026
Language
EN